Transplantation Flashcards

(36 cards)

1
Q
# 1. Define allograft
2. Types of allograft
A
  1. Allograft: The transplant of an organ or tissue from one individual to another of the same species with a different genotype. For example, a transplant from one person to another, but not an identical twin, is an allograft.
  2. Types/examples:
  • Solid organs (kidney, liver, heart, lung, pancreas)
  • Small bowel
  • Free cells (bone marrow stem cells, pancreas islets)
  • Temporary: blood, skin (burns)
  • Privileged sites: cornea
  • Framework: bone, cartilage, tendons, nerves
  • Composite: hands, face
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the most common transplant performed?

A

Kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How can transplant outcomes be improved?

A
  • Improved surgical technique
  • Improved pre- and post-transplant patient management and monitoring

–Drug levels

–Infections, cardiovascular disease, diabetes,…

•Better understanding of transplant immunology

–>Better immunosuppressive agents

–> Prevention, diagnosis and treatment of graft rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 3 phases of the immune response to a transplanted graft?

A
  • Phase 1: recognition of foreign antigens
  • Phase 2: activation of antigen-specific lymphocytes
  • Phase 3: effector phase of graft rejection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the most relevant protein variations in clinical transplantation?

A
  • ABO blood group
  • HLA (human leukocyte antigens) coded in chromosome 6 by Major histocompatibility complex (MHC)

Other determinants - minor histocompatibility genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the two major components to rejection?

A

–T cell-mediated rejection

–Antibody-mediated rejection (B cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  1. What are HLA (Human leukocyte antigens)
  2. what do they do?
  3. What are their classes and variability?
A
  1. Cell surface proteins
  2. Presentation of foreign antigens on HLA molecules to T cells is central to T cell activation
  3. Classes:
  • HLA Class I (A,B,C)– expressed on all cells
  • HLA Class II (DR, DQ, DP) – expressed on antigen-presenting cells but also can be upregulated on other cells under stress
  • Highly polymorphic – hundreds of alleles for each locus (for example: A1, A2, A3 – A372 and rising…)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Why does everyone have a variety of HLA proteins?

A

To maximise diversity against infections

•The variability in HLA molecules in the population provides a source for immunisation against the transplanted organ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the different MHC/HLA combinations

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the differences between MHC Class 1 and 2?

A

MHC Class 1: MHC class 1 are a class of major histocompatibility complex molecules found on the surface of all nucleated cells in mammals.

MHC Class 2: MHC class 2 are a class of major histocompatibility complex molecules mainly found on antigen presenting cells such as macrophages, dendritic cells, and B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When comparing HLA differences, what is the maximum amount of mismatches allowed across HLA-A, HLA-B and HLA-DR?

A

6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How many mismatches are in this example?

A

Remember HLA are proteins, so they come with two alleles, that may code for different versions of that HLA protein.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is T cell mediated rejection?

A

T cells require presentation of the foreign HLA antigens by a professional antigen presenting cell (APC), in the context of HLA, to initiate activation of alloreactive T-cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the role of alloreactive T cells? Describe the direct and indirect pathways that lead to transplant rejection

A

T-cell alloreactivity drives transplant rejection. Alloreactive recognition is believed to proceed with limited specificity, accounting for the high numbers of alloreactive T cells in humans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the three signals that activate T cells after a transplant

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe how graft infiltration occurs with the help of cytotoxic T cells and macrophages

A

Graft infiltration by alloreactive CD4+ cells

“Cytotoxic” T cells

  • Release of toxins to kill target
    • Granzyme B
  • Punch holes in target cells
    • Perforin
  • Apoptotic cell death
    • Fas -Ligand

Macrophages

  • Phagocytosis
  • Release of proteolytic enzymes
  • Production of cytokines
  • Production of oxygen radicals and nitrogen radicals
17
Q

On a graft biopsy, what can be seen when acute cellular rejection has occurred?

A

Interstitial inflammation and tubulitis

18
Q

What are the 3 phases of antibody-mediated rejection?

A

Phase 1 – exposure to foreign antigen

Phase 2 - proliferation and maturation of B cells with antibody production

Phase 3 – effector phase; antibodies bind to graft endothelium (capillaries of glomerulus and around tubules, arterial)

19
Q

Describe the effectors in anti-body mediated rejection and whether they are naturally occuring or not

A

–Anti-A or anti-B antibodies are naturally occurring

–anti-HLA antibodies are not naturally occurring

  • Pre-formed – previous exposure to epitopes (previous transplantation, pregnancy, transfusion)
  • Post-formed - arise after transplantation
20
Q

Describe the action of antibodies in infection

A

B cells produce specific antibodies against the cell surface proteins on donor tissue, in an attempt to destroy it as it is considered a foreign article.

Complement is then activated allowing for cell adhesion, and attraction of other cells to cause cell necrosis to the cells of the donor tissue

21
Q

Describe how antibodies act to reject donor organs in transplant

A

B cells produce specific antibodies against the cell surface proteins on donor tissue, in an attempt to destroy it as it is considered a foreign article.

Complement is then activated allowing for cell adhesion, and attraction of other cells to cause cell necrosis to the cells of the donor tissue

22
Q

What makes the ABO blood groups?

A
  • A and B glycoproteins on red blood cells but also endothelial lining of blood vessels in transplanted organ
  • Naturally occurring anti-A and anti-B antibodies
23
Q

Describe what

  1. antibodies in plasma
  2. antigens on red blood cells

will be for blood groups A, B, AB and O

24
Q

Describe tissue rejection

A
  • T-cell mediated, antibody-mediated or combined
  • Both cause graft dysfunction (e.g. raised creatinine, raised LFT)
  • Graft biopsy: management and outcome are different
25
Describe the prevention and treatment of graft rejection
•Preventing rejection: * A. AB/HLA matching * B. Screening for anti-HLA antibodies * C. Immunosuppression: dampen the immune system of the recipient •Treating rejection: * More immunosuppression •Always balance the need for immunosuppression with the risk of infection/malignancy/drug toxicity
26
1. Describe AB/HLA typing in transplantation 2. When in HLA matching important in organ transplantation?
1. * Part of the organ allocation procedure * Encourage living donation from "blood" relatives 2. •HLA matching is an important part of organ allocation procedure * Bone marrow * Kidney •HLA matching not as important * Heart * Lung •Liver - ?
27
How is donor and receipient HLA type determined?
•PCR-based DNA sequence analysis determines the individuals genotype
28
When should antibodies be screened for during transplantation proceedings?
* Before transplantation * At time of transplantation: when a specific deceased donor kidney has been assigned to the patient * After transplantation, repeat measurements to check for new antibody production
29
What 3 main types of assays are used to screen for anti-HLA antibodies?
–Cytotoxicity assays - does the recipient serum kill the donor’s lymphocytes in the presence of complement? – detection of cell death using vital dyes –Flow cytometry - does the recipient’s serum bind to the donor’s lymphocytes (bound antibody detected by fluorescently-labelled anti-human Ig) –Solid phase assays - does the recipient’s serum bind to recombinant single HLA molecules attached to a solid support such as beads (bound antibody detected by fluorescently-labelled anti-human Ig)
30
How is transplant rejection managed?
More immunosuppression * Targeting T cell activation * Mycophenolate mofentil - affect nucleotide synthesis * Daclizumab - Anti-CD25 mAB * Alemtuzumab - Anti-CD52 mAB * Azathioprine - affects the cell cycle * Tacrolimus - Calcineurin inhibitors * Targeting antibody-mediated damage * Anti-CD20 antibodies * BAFF inhibitors * Proteasome inhibitors * Complement inhibitors * CD28/B7 blockade * Anti-CD40
31
Describe some modern transplant immunosuppression
* Induction agent ex. OKT3/ATG, anti-CD52, anti-CD25 (anti-IL2R) * Base-line immunosuppression: CNI inhibitor + MMF or Aza, with or without steroids * Treatment of episodes of acute rejection: * Cellular: steroids (MP IV 3x 60mg/kg then oral), ATG/OKT3 * Antibody-mediated: IVIG, plasma exchange, anti-C5, anti-CD20
32
What is haematopoietic stem cell transplants used for?
* Haematological and lymphoid cancers * Acquired (autoimmune) or inherited deficiencies in marrow cells such as errors of metabolism or immunodeficiencies
33
How does graft vs host disease occur in haemotopoietic stem cell transplants?
* Eliminate hosts immune system (total body irradiation; cyclophophamide; other drugs) * Replace with own (autologous) or HLA-matched donor (allogeneic) bone marrow * Allogeneic HSCT leads to reaction of donor lymphocytes against host tissues * Related to degree of HLA-incompatibility * Also graft-versus-tumour effect * GVHD prophylaxis: Methotrexate/Cyclosporine
34
1. What is graft vs host disease? 2. What happens? 3. Treatments
1. Injury induced by preparative regime before HSCT 2. * Skin: rash * Gut: nausea, vomiting, abdominal pain, diarrheoa, bloody stool * Liver: jaundice 3. Treat with corticosteroids
35
Describe post-transplantation infections
•Increased risk for conventional infections –Bacterial, viral, fungal •Opportunistic infections – normally relatively harmless infectious agents give severe infections because of immune compromise –Cytomegalovirus –BK virus –Pneumocytis carinii
36
Describe post transplantation malignancy
–Viral associated (x 100) * Kaposi’s sarcoma (HHV8) * Lymphoproliferative disease (EBV) –Skin Cancer (x20) –Risk of other cancers eg lung, colon also increased (x 2-3)